ATI LPN
Pharmacology and the Nursing Process 10th Edition Test Bank
Chapter 20 : Cholinergic Drugs Questions
Question 1 of 5
A patient has been taking donepezil for 2 weeks as part of the treatment for early stages of Alzheimer's disease. Her daughter calls the prescriber's office and is upset because -Mother has not improved one bit! Which response by the nurse is appropriate?
Correct Answer: C
Rationale: Donepezil may take up to 6 weeks to show improvement in Alzheimer's symptoms. It is not a cure, and dosage changes or administration adjustments should not be made without prescriber approval.
Question 2 of 5
A patient who has been diagnosed with Sj?¶gren's syndrome will be given cevimeline for the treatment of xerostomia. The nurse will monitor for what therapeutic effect?
Correct Answer: B
Rationale: Cevimeline, a direct-acting cholinergic drug, stimulates salivation in patients with xerostomia (dry mouth) associated with Sj?¶gren's syndrome. The other options are incorrect.
Question 3 of 5
The nurse is reviewing the mechanism of action of cholinergic drugs. The desired effects of cholinergic drugs come from the stimulation of which receptors?
Correct Answer: A
Rationale: The desired effects of cholinergic drugs come from muscarinic receptor stimulation. Many undesirable adverse effects are due to nicotinic receptor stimulation. The other options are incorrect.
Question 4 of 5
A patient calls the clinic to speak to the nurse about taking an herbal product that contains ginkgo (Ginkgo biloba) to -help my memory. He states that he has read much information about the herbal product. Which statement by the patient indicates a need for further education?
Correct Answer: C
Rationale: Drug interactions may occur between ginkgo and aspirin or nonsteroidal anti-inflammatory drugs like ibuprofen, increasing bleeding risk. The other statements are correct.
Question 5 of 5
A patient is receiving a dose of edrophonium. The nurse recognizes that this drug is given to determine the diagnosis of which disease?
Correct Answer: C
Rationale: Edrophonium, an indirect-acting cholinergic drug, is commonly used to diagnose myasthenia gravis by improving muscle strength temporarily. It is not used to diagnose Parkinson's disease, multiple sclerosis, or Alzheimer's disease.